News - Par Pharmaceutical, BioAlliance Pharma


Popular Filters

1 to 25 of 30 results

Par Pharmaceutical appoints Terrance Coughlin as chief operating officer

Par Pharmaceutical appoints Terrance Coughlin as chief operating officer


Par Pharmaceutical Companies (NYSE: PRX) has announced the appointment of Terrance Coughlin as chief…

BoardroomPar PharmaceuticalPar PharmaceuticalsPharmaceuticalUSA

BioAlliance Pharma licenses Sitavig to Innocutis in North America


French drug developer BioAlliance Pharma has executed a licensing accord with the USA’s Innocutis Holdings…

Anti-viralsBioAlliance PharmaBiotechnologyInnocutis HoldingsLicensingNorth AmericaSitavig

Par Pharmaceutical to acquire JHP Pharmaceutical


US privately-held Par Pharmaceutical has entered into a definitive agreement to acquire JHP Group Holdings,…

GenericsJHP PharmaceuticalsMergers & AcquisitionsPar Pharmaceutical

Acura Pharma settles with Par and Impax over Oxecta

Acura Pharma settles with Par and Impax over Oxecta


US specialty pharma firm Acura Pharmaceuticals saw its shares leap as much as 28% after it said that…

Acura PharmaceuticalsGenericsImpax LaboratoriesLicensingNeurologicalNorth AmericaOxectaPar PharmaceuticalPatents

Horizon Pharma in Duexis patent settlement


Horizon Pharma (Nasdaq: HZNP) says it has entered into settlement and license agreements with Par Pharmaceutical…

Anti-Arthritics/RheumaticsDuexisGenericsHorizon PharmaNorth AmericaPar PharmaceuticalPatentsPharmaceutical

BioAlliance Pharma' Sitavig shows marked efficacy in treating cold sores


French drugmaker BioAlliance Pharma (Euronext Paris: BIO) has presented positive results of the pharmacokinetic…

Anti-viralsBioAlliance PharmaPharmaceuticalResearchSitavig

BioAlliance updates on Livatag development


French orphan cancer drug developer BioAlliance Pharma (Euronext Paris: BIO) says that the International…

BioAlliance PharmaLivatagNexavarOncologyPharmaceuticalResearch

BioAlliance Pharma's Sitavig OKed by US FDA for Herpes labialis


French drugmaker BioAlliance Pharma (Euronext Paris - BIO) has received marketing authorization from…

Anti-viralsBioAlliance PharmaNorth AmericaPharmaceuticalRegulationSitavig

BioAlliance Pharma pursues development plan for Loramyc in Japan through partner Sosei


French orphan oncology and supportive care specialist BioAlliance Pharma (Euronext Paris: BIO) says its…

Antibiotics and Infectious diseasesAsia-PacificBioAlliance PharmaLoramycOravigPharmaceuticalRegulationResearchSosei

Par Pharma agrees $45 million settlement over off-label Megace ES promotion


US generic drugmaker Par Pharmaceutical NYSE: PRX) pleaded guilty in federal court yesterday (March 6)…

FinancialGenericsLegalMarkets & MarketingMegace ESMetabolicsNorth AmericaPar PharmaceuticalPharmaceutical

BioAlliance Pharma extends Ph II Validive trial to USA


French biotech firm BioAlliance Pharma (Euronext Paris - BIO) has announced the extension of its Phase…

BioAlliance PharmaBiotechnologyclonidine LauriadOncologyResearchValidive

BioAlliance says partner Vestiq debuts Oravig in USA


French biotech firm BioAlliance Pharma (Euronext Paris - BIO) has announces the launch of Oravig (miconazole…

BioAlliance PharmaBiotechnologyLoramycMarkets & MarketingNorth AmericaOncologyOravigPharmaceuticalVestiq Pharmaceuticals

BioAlliance gains registration of Sitavig in eight European countries


French biotech firm BioAlliance Pharma (Euronext Paris: BIO) has announced the approval of Sitavig (acyclovir…

Anti-viralsBioAlliance PharmaBiotechnologyEuropeRegulationSitavig

Validity of certain patent claims covering Santarus' Zegerid capsule and powder upheld


US drugmaker Santarus (Nasdaq: SNTS) saw its shares leap 14.2% to $7.06 in regular trading on September…

GenericsLegalNorth AmericaPar PharmaceuticalPatentsPharmaceuticalSantarusZegerid

Mylan settles litigation with Somaxon relating to its generic Silenor


US generic drugmaker Mylan (Nasdaq: MYL) and its subsidiary, Mylan Pharmaceuticals have entered into…

LegalMylan LaboratoriesNeurologicalNorth AmericaPar PharmaceuticalPatentsPharmaceuticalSilenorSomaxon Pharmaceuticals

TPG to acquire Par Pharma for $1.9 billion


Par Pharmaceutical (NYSE: PRX), a USA-based maker of generic drugs and niche innovative proprietary pharmaceuticals,…

GenericsMergers & AcquisitionsPar PharmaceuticalTPG

Teva gets rights to BioAlliance's Sitavig in Israel


French drugmaker BioAlliance Pharma (Euronext Paris: BIO) has signed an exclusive license agreement for…

Anti-viralsBioAlliance PharmaLicensingPharmaceuticalRest of the WorldSitavigTeva Pharmaceutical Industries

BioAlliance's Sitavig NDA "receivable" by US FDA


French biotech firm BioAlliance Pharma (Euronext Paris: BIO) has announced the receivability of its Sitavig…

Anti-viralsBioAlliance PharmaBiotechnologyNorth AmericaRegulationSitavigSitavir

BioAlliance Pharma updates on Amep biotherapy development


its application for a Phase I/II clinical trial with Amep in the metastatic melanoma, and the signing…

AmepBioAlliance PharmaOncologyPharmaceuticalResearch

FDA decides Teva is sole first-to-file on Provigil; Mylan argues ruling


Israel-based Teva Pharmaceutical Industries (Nasdaq: TEVA) said on April 5 that the US Food and Drug…

CephalonGenericsLegalModafinilMylan LaboratoriesNeurologicalNorth AmericaPar PharmaceuticalProvigilRegulationTeva Pharmaceutical Industries

Horizon Pharma sues Par for infringing Duexis patent


Horizon Pharma (Nasdaq: HZNP) has filed a patent infringement lawsuit in the US District Court for the…

DuexisGenericsHorizon PharmaLegalNeurologicalNorth AmericaPar PharmaceuticalPatents

NovaDel regains rights for ondansetron oral spray product


New Jersey, USA-based NovaDel Pharma (OTCBB: NVDL) has announced the termination of certain license agreements…

BioAlliance PharmaLicensingNovaDel PharmaOncologyondansetronPar PharmaceuticalPharmaceuticalTalon Therapeutics

1 to 25 of 30 results

Company Spotlight



Back to top